Kinshasa: The World Health Organization (WHO) has announced that early clinical trials of experimental treatments for the Bundibugyo strain of Ebola are showing encouraging results in the Democratic Republic of the Congo (DRC), offering new hope in the fight against one of the country's deadliest outbreaks.
Health experts say this is an important milestone because there are currently no approved medicines or vaccines designed specifically for the Bundibugyo strain of the Ebola virus. While effective treatments and vaccines exist for the more common Zaire strain, the Bundibugyo variant has remained a major challenge for researchers due to the limited number of outbreaks over the years.
The latest outbreak in eastern Congo has become one of the largest ever linked to the Bundibugyo strain. According to recent figures released by health authorities, more than 3,800 confirmed infections have been recorded, while the death toll has climbed above 1,700. The disease continues to spread despite months of intensive efforts by local and international health teams.
WHO said the treatment studies were able to begin quickly because research plans had already been prepared before the outbreak occurred. This allowed scientists to launch clinical trials within weeks after the virus was identified, instead of waiting months to organize the research.
The main treatment trial is taking place in Ituri province and is being carried out by WHO in partnership with the humanitarian medical organisation ALIMA and Médecins Sans Frontières, also known as Doctors Without Borders. More than 50 patients have already joined the study, with additional participants expected in the coming weeks.
Researchers are testing an experimental monoclonal antibody treatment known as MBP134, which was developed by Mapp Biopharmaceutical. Another group of patients is receiving the same treatment together with the antiviral medicine remdesivir, which is produced by Gilead Sciences and has previously been used against several viral diseases.
At the same time, scientists have launched another study involving Obeldesivir, an oral antiviral medicine also developed by Gilead Sciences. This trial is focusing on people who have been in close contact with Ebola patients to determine whether the medicine can prevent infection after exposure to the virus.
WHO officials stressed that the research is still at an early stage and that it is too soon to confirm whether the treatments are effective. However, the first results have been encouraging enough to continue expanding the studies.
Alongside treatment research, work is also progressing on vaccines targeting the Bundibugyo strain. A vaccine developed by the University of Oxford and the Serum Institute of India has already entered Phase 1 clinical trials in the United Kingdom. Another vaccine candidate developed by Moderna is expected to begin early human testing in Canada in the near future.
Scientists are also examining whether the existing Ebola vaccine produced by Merck for the Zaire strain could provide some level of protection against the Bundibugyo virus. Laboratory and animal studies are expected to help answer that question before larger human studies are considered.
Despite these scientific advances, health officials warn that controlling the outbreak remains extremely difficult. Nearly 80 percent of new infections are now being linked to community transmission rather than known contacts already being monitored by health workers. This makes it much harder to identify infected individuals quickly and stop further spread.
The response has also been complicated by armed conflict in eastern Congo, frequent population movement, attacks on health facilities and continuing mistrust of health workers in some communities. Aid organisations say these challenges have slowed contact tracing, delayed treatment and made vaccination campaigns more difficult.
Funding has become another concern. WHO has previously warned that the Ebola response remains underfunded, raising fears that shortages of resources could affect surveillance, laboratory testing and patient care if additional international support is not secured.
Meanwhile, neighbouring Uganda recently declared its own Bundibugyo Ebola outbreak officially over after completing the required 42 days without any new confirmed cases. Health experts say Uganda's experience shows that rapid isolation of patients, intensive contact tracing and strong community cooperation can successfully contain the disease.
Even so, WHO has cautioned that the risk of cross border transmission remains because of regular travel between the two countries. Health authorities continue to strengthen screening measures and surveillance in border areas to detect any new infections quickly.
While much work remains before any new treatment or vaccine receives approval, the progress being made during the current outbreak is giving scientists hope that effective medical tools for the Bundibugyo strain may finally be within reach. If the ongoing studies continue to produce positive results, they could transform the global response to future outbreaks of this rare but deadly form of Ebola.